NASDAQ:BLFS BioLife Solutions - BLFS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding BioLife Solutions, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $24.43 -1.59 (-6.11%) (As of 02/7/2023 04:18 PM ET) Add Compare Share Share Today's Range$23.75▼$26.0450-Day Range$16.95▼$26.0752-Week Range$10.40▼$29.92Volume266,112 shsAverage Volume345,588 shsMarket Capitalization$1.04 billionP/E RatioN/ADividend YieldN/APrice Target$31.20 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media BioLife Solutions MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside28.0% Upside$31.20 Price TargetShort InterestHealthy5.92% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.07Based on 8 Articles This WeekInsider TradingSelling Shares$2.72 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.63) to ($0.34) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.29 out of 5 starsMedical Sector259th out of 1,029 stocksElectromedical Equipment Industry8th out of 23 stocks 3.5 Analyst's Opinion Consensus RatingBioLife Solutions has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $31.20, BioLife Solutions has a forecasted upside of 28.0% from its current price of $24.38.Amount of Analyst CoverageBioLife Solutions has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted5.92% of the float of BioLife Solutions has been sold short.Short Interest Ratio / Days to CoverBioLife Solutions has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in BioLife Solutions has recently decreased by 5.67%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBioLife Solutions does not currently pay a dividend.Dividend GrowthBioLife Solutions does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BLFS. Previous Next 3.4 News and Social Media Coverage News SentimentBioLife Solutions has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for BioLife Solutions this week, compared to 1 article on an average week.Search Interest2 people have searched for BLFS on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added BioLife Solutions to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioLife Solutions insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,715,234.00 in company stock.Percentage Held by InsidersOnly 3.30% of the stock of BioLife Solutions is held by insiders.Percentage Held by Institutions89.82% of the stock of BioLife Solutions is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BioLife Solutions are expected to grow in the coming year, from ($0.63) to ($0.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioLife Solutions is -9.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioLife Solutions is -9.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioLife Solutions has a P/B Ratio of 2.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About BioLife Solutions (NASDAQ:BLFS) StockBioLife Solutions, Inc. engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs, generic blood stem cell freezing and cell thawing media products and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1987 and is headquartered in Bothell, WA.Read More Receive BLFS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioLife Solutions and its competitors with MarketBeat's FREE daily newsletter. Email Address BLFS Stock News HeadlinesFebruary 4, 2023 | americanbankingnews.comInsider Selling: BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Sells 10,000 Shares of StockJanuary 17, 2023 | finance.yahoo.comBioLife Solutions Announces 2023 Analyst Day & Participation in Upcoming Investor ConferencesFebruary 7, 2023 | Wall Street Watch Dogs (Ad)The #1 Energy Stock to BuyThe next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…January 10, 2023 | finance.yahoo.comBioLife Solutions Named One of Seattle Business Magazine's Washington's Best Companies to Work ForJanuary 9, 2023 | finance.yahoo.comBioLife Solutions Announces 2022 Fourth Quarter and Full Year Preliminary Unaudited Revenue and Introduces 2023 Revenue GuidanceJanuary 7, 2023 | seekingalpha.comBioLife Solutions: Inventory Movement A Key Benchmarking Factor, Retain HoldJanuary 6, 2023 | finance.yahoo.comIs BioLife Solutions, Inc. (NASDAQ:BLFS) Potentially Undervalued?January 5, 2023 | forbes.comBioLife SolutionsFebruary 7, 2023 | Wall Street Watch Dogs (Ad)The #1 Energy Stock to BuyThe next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…December 19, 2022 | finance.yahoo.comBioLife Solutions to Announce Preliminary 2022 Revenue and Introduce 2023 Revenue Guidance on January 9, 2023December 18, 2022 | finance.yahoo.comShould You Invest in BioLife Solutions (BLFS)?December 15, 2022 | msn.comBioLife Solutions's Return On Capital Employed InsightsDecember 10, 2022 | finance.yahoo.comInvestors push BioLife Solutions (NASDAQ:BLFS) 11% lower this week, company's increasing losses might be to blameNovember 21, 2022 | finance.yahoo.comBioLife Solutions Expands Intellectual Property EstateNovember 17, 2022 | finance.yahoo.comBioLife Solutions Named in BioSpace Best Places to Work in Biopharma 2023 ReportNovember 11, 2022 | finance.yahoo.comBioLife Solutions Third Quarter 2022 Earnings: Misses ExpectationsNovember 9, 2022 | seekingalpha.comBioLife Solutions, Inc. (BLFS) Q3 2022 Earnings Call TranscriptNovember 9, 2022 | finance.yahoo.comBioLife Solutions, Inc. (BLFS) Reports Q3 Loss, Lags Revenue EstimatesNovember 9, 2022 | finance.yahoo.comBioLife Solutions Reports Third Quarter 2022 Financial ResultsNovember 8, 2022 | msn.comEarnings Outlook For BioLife SolutionsNovember 3, 2022 | finance.yahoo.comIs There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 49% Undervaluation?October 11, 2022 | finance.yahoo.comCSafe and BioLife Solutions, Inc. announce partnership to expand supply chain solutions for the cell and gene therapy marketOctober 3, 2022 | finance.yahoo.comBioLife Solutions Announces COO to Retire and Join Board of DirectorsSeptember 26, 2022 | benzinga.comBioLife Sciences Inc. (OTC: BLFE) Enters Into Negotiations for Exclusive Licensing Deal With Canadian FirmSeptember 17, 2022 | reuters.comBioLife Solutions IncAugust 25, 2022 | finance.yahoo.comBioLife Solutions Appoints Cell Therapy Executive Timothy L. Moore to its Board of DirectorsAugust 10, 2022 | finance.yahoo.comBioLife Sciences Retains Benzinga for Marketing CampaignSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive BLFS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioLife Solutions and its competitors with MarketBeat's FREE daily newsletter. Email Address BLFS Company Calendar Last Earnings11/09/2022Today2/07/2023Next Earnings (Estimated)2/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BLFS CUSIPN/A CIK834365 Webwww.biolifesolutions.com Phone(425) 402-1400Fax425-402-1433Employees432Year FoundedN/APrice Target and Rating Average Stock Price Forecast$31.20 High Stock Price Forecast$34.00 Low Stock Price Forecast$29.00 Forecasted Upside/Downside+27.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,640,000.00 Net Margins-67.70% Pretax Margin-72.07% Return on Equity-7.50% Return on Assets-6.49% Debt Debt-to-Equity Ratio0.06 Current Ratio3.68 Quick Ratio2.76 Sales & Book Value Annual Sales$119.16 million Price / Sales8.77 Cash FlowN/A Price / Cash FlowN/A Book Value$11.80 per share Price / Book2.07Miscellaneous Outstanding Shares42,770,000Free Float41,355,000Market Cap$1.04 billion OptionableNot Optionable Beta1.86 Key ExecutivesMichael P. RiceChairman & Chief Executive OfficerGeraint PhillipsSenior Vice President-Global OperationsTroy WichtermanChief Financial OfficerAby J. MathewChief Scientific Officer & Executive VPRoderick de GreefDirectorKey CompetitorsViewRayNASDAQ:VRAYOutset MedicalNASDAQ:OMZynexNASDAQ:ZYXIAxoGenNASDAQ:AXGNEdap TmsNASDAQ:EDAPView All CompetitorsInsiders & InstitutionsZweig DiMenna Associates LLCBought 16,000 shares on 2/7/2023Ownership: 0.900%Envestnet Asset Management Inc.Sold 7,563 shares on 2/7/2023Ownership: 0.097%LPL Financial LLCBought 2,183 shares on 2/7/2023Ownership: 0.060%Handelsbanken Fonder ABBought 24,500 shares on 2/7/2023Ownership: 0.057%Los Angeles Capital Management LLCBought 15,401 shares on 2/6/2023Ownership: 0.104%View All Insider TransactionsView All Institutional Transactions BLFS Stock - Frequently Asked Questions Should I buy or sell BioLife Solutions stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BLFS shares. View BLFS analyst ratings or view top-rated stocks. What is BioLife Solutions' stock price forecast for 2023? 1 analysts have issued 1-year price targets for BioLife Solutions' shares. Their BLFS share price forecasts range from $29.00 to $34.00. On average, they anticipate the company's share price to reach $31.20 in the next twelve months. This suggests a possible upside of 28.0% from the stock's current price. View analysts price targets for BLFS or view top-rated stocks among Wall Street analysts. How have BLFS shares performed in 2023? BioLife Solutions' stock was trading at $18.20 at the beginning of 2023. Since then, BLFS stock has increased by 34.0% and is now trading at $24.38. View the best growth stocks for 2023 here. Are investors shorting BioLife Solutions? BioLife Solutions saw a drop in short interest in January. As of January 15th, there was short interest totaling 2,330,000 shares, a drop of 5.7% from the December 31st total of 2,470,000 shares. Based on an average trading volume of 379,600 shares, the days-to-cover ratio is presently 6.1 days. Approximately 5.9% of the company's stock are short sold. View BioLife Solutions' Short Interest. When is BioLife Solutions' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023. View our BLFS earnings forecast. How were BioLife Solutions' earnings last quarter? BioLife Solutions, Inc. (NASDAQ:BLFS) announced its quarterly earnings results on Wednesday, November, 9th. The medical equipment provider reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.12) by $0.03. The medical equipment provider earned $40.75 million during the quarter, compared to analysts' expectations of $41.63 million. BioLife Solutions had a negative net margin of 67.70% and a negative trailing twelve-month return on equity of 7.50%. What guidance has BioLife Solutions issued on next quarter's earnings? BioLife Solutions issued an update on its FY 2022 earnings guidance on Saturday, January, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $161.90 million-$161.90 million, compared to the consensus revenue estimate of $160.92 million. What is Mike Rice's approval rating as BioLife Solutions' CEO? 14 employees have rated BioLife Solutions Chief Executive Officer Mike Rice on Glassdoor.com. Mike Rice has an approval rating of 100% among the company's employees. This puts Mike Rice in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 89.0% of employees surveyed would recommend working at BioLife Solutions to a friend. What other stocks do shareholders of BioLife Solutions own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioLife Solutions investors own include Micron Technology (MU), AbbVie (ABBV), Cara Therapeutics (CARA), Gilead Sciences (GILD), Pfizer (PFE), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Twilio (TWLO) and Verastem (VSTM). What is BioLife Solutions' stock symbol? BioLife Solutions trades on the NASDAQ under the ticker symbol "BLFS." Who are BioLife Solutions' major shareholders? BioLife Solutions' stock is owned by a number of retail and institutional investors. Top institutional investors include Stephens Investment Management Group LLC (0.92%), Zweig DiMenna Associates LLC (0.90%), New York State Common Retirement Fund (0.83%), Peregrine Capital Management LLC (0.67%), Stephens Inc. AR (0.34%) and Los Angeles Capital Management LLC (0.10%). Insiders that own company stock include Aby J Mathew, Aby J Mathew, Amy Duross, Andrew G Hinson, Andrew G Hinson, Casdin Partners Master Fund, L, Greef Roderick De, James Mathers, Joseph C Schick, Karen A Foster, Karen A Foster, Marcus Schulz, Michael Rice, Of The University Of C Regents, Raymond W Cohen, Sarah Aebersold, Thomas Girschweiler, Todd Berard, Troy Wichterman and Walter Villiger. View institutional ownership trends. How do I buy shares of BioLife Solutions? Shares of BLFS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is BioLife Solutions' stock price today? One share of BLFS stock can currently be purchased for approximately $24.38. How much money does BioLife Solutions make? BioLife Solutions (NASDAQ:BLFS) has a market capitalization of $1.04 billion and generates $119.16 million in revenue each year. The medical equipment provider earns $-7,640,000.00 in net income (profit) each year or ($2.48) on an earnings per share basis. How many employees does BioLife Solutions have? The company employs 432 workers across the globe. How can I contact BioLife Solutions? BioLife Solutions' mailing address is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. The official website for the company is www.biolifesolutions.com. The medical equipment provider can be reached via phone at (425) 402-1400, via email at rdegreef@biolifesolutions.com, or via fax at 425-402-1433. This page (NASDAQ:BLFS) was last updated on 2/7/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.